Outcomes of ablation in Wolff-Parkinson-White-syndrome: Data from the German Ablation Registry.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 01 2021
Historique:
received: 11 08 2020
revised: 28 08 2020
accepted: 31 08 2020
pubmed: 6 9 2020
medline: 28 5 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

Catheter ablation is recommended for symptomatic WPW-syndrome. Commonly perceived low recurrence rates were challenged recently. We sought to identify patient strata at increased risk. Of 12,566 patients enrolled at 52 German Ablation Registry sites from 2007 to 2010, 789 were treated for WPW-syndrome. Patients were included for symptomatic palpitations and tachycardia documentation. Follow-up duration was one year. Overall complications were defined as serious, access-related, and ablation-related. We adjudicated WPW-recurrence for re-ablation during follow-up. Risk strata included: admission for repeat ablation at registry entry; accessory pathway localization; antiarrhythmic medical treatment before the ablation. WPW-syndrome patients were 42.8 ± 16.2 years on average; 39.9% were women. A majority of 95.9% was symptomatic; in 84.4%, a tachycardia was documented. Seventy-six (9.6%) patients presented for repeat procedures. Accessory pathways were located in the left atrium (71.4%), right atrium (21.1%), septum (4.4%), or coronary sinus diverticula (2.1%). Prior antiarrhythmic medication was used in 43.7% of patients. No serious events occurred. The overall complication rate was 2.5% (ablation related 1.2%, access-related 1.3%). Major determinants for complications were presentation for re-ablation as registry index procedure (6.9% vs 2.2%; p = 0.016) and septal pathway location (left 2.0% vs septal 9.1%, p = 0.014). The overall re-ablation rate was 9.7%. Usage of prior antiarrhythmic medication was associated with higher recurrence rates (12.2% vs. 7.6%; p = 0.035). Patients at higher complication risk may be identified by repeat procedure and septal pathway location. Prior antiarrhythmic medication was associated with higher recurrence rates. Our findings may help improving peri-procedural patient management and information.

Identifiants

pubmed: 32890614
pii: S0167-5273(20)33729-3
doi: 10.1016/j.ijcard.2020.08.102
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-112

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Johannes Brado (J)

Department of Medicine I, University Hospital, LMU Munich, Germany; German Centre for Cardiovascular Research (DZHK); Partner Site: Munich Heart Alliance, Munich, Germany.

Matthias Hochadel (M)

Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.

Jochen Senges (J)

Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.

Karl-Heinz Kuck (KH)

LANS Cardio, Hamburg, Germany.

Dietrich Andresen (D)

Evangelic Hospital Hubertus, Berlin, Germany.

Stephan Willems (S)

Asklepios Hospital St. Georg, Hamburg, Germany.

Florian Straube (F)

Department of Cardiology and Internal Medicine, Clinic Munich Bogenhausen, Germany.

Thomas Deneke (T)

Department of Cardiology II, Rhön-Hospital, Bad Neustadt a. d. Saale, Germany.

Lars Eckardt (L)

Department of Cardiology II, University Hospital Münster, Münster, Germany.

Johannes Brachmann (J)

Department of Cardiology, Hospital Coburg, Coburg, Germany.

Stefan Kääb (S)

Department of Medicine I, University Hospital, LMU Munich, Germany; German Centre for Cardiovascular Research (DZHK); Partner Site: Munich Heart Alliance, Munich, Germany.

Moritz F Sinner (MF)

Department of Medicine I, University Hospital, LMU Munich, Germany; German Centre for Cardiovascular Research (DZHK); Partner Site: Munich Heart Alliance, Munich, Germany. Electronic address: msinner@med.lmu.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH